 POEMS Syndrome
"POEMS Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)
| Descriptor ID |
D016878
|
| MeSH Number(s) |
C10.668.829.800.700 C15.378.147.780.750 C16.131.077.703 C20.683.780.750
|
| Concept/Terms |
POEMS Syndrome- POEMS Syndrome
- Syndrome, POEMS
- Takatsuki's Syndrome
- Syndrome, Takatsuki's
- Takatsuki Syndrome
- Polyneuropathy Organomegaly
- Organomegalies, Polyneuropathy
- Organomegaly, Polyneuropathy
- Polyneuropathy Organomegalies
- Crow-Fukase Syndrome
- Crow Fukase Syndrome
- Syndrome, Crow-Fukase
- Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome
|
Below are MeSH descriptors whose meaning is more general than "POEMS Syndrome".
Below are MeSH descriptors whose meaning is more specific than "POEMS Syndrome".
This graph shows the total number of publications written about "POEMS Syndrome" by people in UAMS Profiles by year, and whether "POEMS Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 2 | 0 | 2 | | 2020 | 3 | 0 | 3 | | 2019 | 2 | 0 | 2 | | 2018 | 3 | 0 | 3 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2015 | 4 | 0 | 4 | | 2014 | 3 | 0 | 3 | | 2013 | 2 | 0 | 2 | | 2012 | 3 | 1 | 4 | | 2011 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "POEMS Syndrome" by people in Profiles over the past ten years.
-
Gao XM, Yu YY, Zhao H, Cai H, Zhang L, Cao XX, Zhou DB, Li J. Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. Ann Hematol. 2021 Nov; 100(11):2755-2761.
-
Zhao H, Gao XM, Cao XX, Zhang L, Zhou DB, Li J. Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome. J Cell Mol Med. 2021 05; 25(9):4307-4315.
-
Chen J, Gao XM, Zhao H, Cai H, Zhang L, Cao XX, Zhou DB, Li J. A highly heterogeneous mutational pattern in POEMS syndrome. Leukemia. 2021 04; 35(4):1100-1107.
-
Feng J, Gao XM, Zhao H, He TH, Zhang CL, Shen KN, Zhang L, Cao XX, Qian M, Zhou DB, Li J. Ischemic stroke in patients with POEMS syndrome. Blood Adv. 2020 07 28; 4(14):3427-3434.
-
Liu LS, Zhang X, Zhao H, Gao XM, Zhou DB, Dai RP, Li J. Reliability of optic disc edema area in estimating the severity of papilledema in patients with POEMS syndrome. Orphanet J Rare Dis. 2020 05 19; 15(1):116.
-
He T, Tian Z, Liu YT, Li J, Zhou DB, Fang Q. Evaluating heart function in patients with POEMS syndrome. Echocardiography. 2019 11; 36(11):1997-2003.
-
Zhao H, Huang XF, Gao XM, Cai H, Zhang L, Feng J, Cao XX, Zhou DB, Li J. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia. 2019 04; 33(4):1023-1029.
-
Li J, Huang XF, Cai QQ, Wang C, Cai H, Zhao H, Zhang L, Cao XX, Gale RP, Zhou DB. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol. 2018 06; 93(6):803-809.
-
Zhao H, Cai H, Wang C, Huang XF, Cao XX, Zhang L, Zhou DB, Li J. Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. Blood Cancer J. 2018 04 04; 8(4):37.
-
Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. Mayo Clin Proc. 2018 04; 93(4):542-544.
-
Zhang X, Cai QQ, Huang XF, Cao XX, Cai H, Zhou DB, Dai RP, Li J. OCULAR MANIFESTATIONS AND TREATMENT OUTCOMES IN CHINESE PATIENTS WITH POEMS SYNDROME. Retina. 2017 Sep; 37(9):1784-1791.
-
Wang C, Guan YZ, Cai QQ, Su W, Zhou DB, Li J. Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond. Medicine (Baltimore). 2016 Apr; 95(16):e3453.
-
Bhutani M, Shahid Z, Schnebelen A, Alapat D, Usmani SZ. Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders. Semin Oncol. 2016 06; 43(3):395-400.
-
Wang C, Su W, Cai QQ, Cai H, Ji W, Di Q, Duan MH, Cao XX, Zhou DB, Li J. Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome. Eur J Haematol. 2016 Jul; 97(1):48-54.
-
Jiang XY, Zhao XP, Ge CW, Zhou DB, Li J. [Morphology Manifestation of Bone Marrow Cells in 155 Newly- Diagnosed Patients with POEMS Syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Aug; 23(4):1165-7.
-
Ye W, Wang C, Cai QQ, Cai H, Duan MH, Li H, Cao XX, Zhou DB, Li J. Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. Nephrol Dial Transplant. 2016 Feb; 31(2):275-83.
-
Cai QQ, Wang C, Cao XX, Cai H, Zhou DB, Li J. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. Eur J Haematol. 2015 Oct; 95(4):325-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|